The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
James R. Berenson
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
James D. Hilger
No relevant relationships to disclose
Robert Dichmann
No relevant relationships to disclose
Dipti Patel-Donnelly
No relevant relationships to disclose
Ralph V. Boccia
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Alberto Bessudo
No relevant relationships to disclose
Laura Stampleman
No relevant relationships to disclose
Donald Gravenor
No relevant relationships to disclose
Shahrooz Eshaghian
No relevant relationships to disclose
Hilda Chamras
No relevant relationships to disclose
Youram Nassir
No relevant relationships to disclose
Regina A. Swift
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Robert A. Vescio
No relevant relationships to disclose